Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREOPANC-3 perioperative versus adjuvant mFOLFIRINOX in resectable pancreatic cancer
NL-OMON58929Phase 3Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Sep 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of irinotecan, oxaliplatin, fluorouracil and folinic acid in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Erasmus MC. Primary endpoint: Overall survival. Started Sep 2024; status: active, not recruiting.
02
Drugs
irinotecanoxaliplatinfluorouracilfolinic acid
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON58929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58929.